TABLE 1.

Currently approved GLP‐1 RAs

	Exenatide (LAR)	Liraglutide	Exenatide (ER)	Albiglutide	Dulaglutide	Lixisenatide	Semaglutide (Injection)	Semaglutide (OA)
Brand name	Byetta	Victoza	Bydureon	Tanzeum	Trulicity	Adlyxin	Ozempic	Rybelsus
Company	AstraZeneca	Novo Nordisk	AstraZeneca	GlaxoSmithKline	Eli Lilly and company	Sanofi	Novo Nordisk	Novo Nordisk
FDA approval date	2005	2010	2012	2014	2014	2016	2017	2019
Dose and administration	5‐10 ug SC, twice daily, prior to meals	0.6‐1.8 mg SC, once daily independent of meals	2 mg SC, once weekly, independent of meals	30‐50 mg SC, once weekly independent of meals	0.75‐1.5 mg SC, once weekly independent of meals	10‐20ug SC, once daily, 1 h before the first meal of the day	0.25‐1 mg SC, once weekly, independent of meals	3‐14 mg PO once daily, at least 30 min before the first food
Elimination half‐life	2.4 h	13 h	2.4 h once release	5 d	4.5 d (0.75 mg) 4.7 d (1.5 mg)	3 h	1 wk	1 wk

Abbreviations: LAR, immediate release; ER, extended release; SC, subcutaneous injection; OA, oral administration; PO, per os.